Edge Rewrite
everything Source code View original
// HTMLRewriter · presentation

This page was redesigned at the edge.

Cloudflare fetched the original article and streamed it through HTMLRewriter to apply an entirely new visual system without rebuilding the source page.

// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2255e38bed1cf83

Jump to content

Merotocin

Add links
From Wikipedia, the free encyclopedia
Merotocin
Clinical data
Other namesFE-202767; FE202767; Carba-1-(4-FBzlGly7)dOT; N-(4-Sulfanylbutanoyl)-L-tyrosyl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-cysteinyl-N-[(4-fluorophenyl)methyl]glycyl-L-leucylglycinamide cyclic (1-5)-thioether
Routes of
administration		Intranasal[1]
Drug classOxytocin receptor agonist
ATC code
  • None
Pharmacokinetic data
Elimination half-life~30 minutes (INTooltip Intranasal administration)[2]
Identifiers
  • (3R,6S,9S,12S,15S)-6-(2-Amino-2-oxoethyl)-N-[2-[[(2S)-1-[(2-amino-2-oxoethyl)amino]-4-methyl-1-oxopentan-2-yl]amino]-2-oxoethyl]-9-(3-amino-3-oxopropyl)-12-[(2S)-butan-2-yl]-N-[(4-fluorophenyl)methyl]-15-[(4-hydroxyphenyl)methyl]-5,8,11,14,17-pentaoxo-1-thia-4,7,10,13,16-pentazacycloicosane-3-carboxamide
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC48H68FN11O12S
Molar mass1042.20 g·mol−1
3D model (JSmol)
  • CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSCCCC(=O)N[C@H](C(=O)N1)Cc2ccc(cc2)O)C(=O)N(Cc3ccc(cc3)F)CC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N
  • InChI=1S/C48H68FN11O12S/c1-5-27(4)42-47(71)56-32(16-17-37(50)62)44(68)57-35(21-38(51)63)45(69)58-36(25-73-18-6-7-40(65)54-34(46(70)59-42)20-28-10-14-31(61)15-11-28)48(72)60(23-29-8-12-30(49)13-9-29)24-41(66)55-33(19-26(2)3)43(67)53-22-39(52)64/h8-15,26-27,32-36,42,61H,5-7,16-25H2,1-4H3,(H2,50,62)(H2,51,63)(H2,52,64)(H,53,67)(H,54,65)(H,55,66)(H,56,71)(H,57,68)(H,58,69)(H,59,70)/t27-,32-,33-,34-,35-,36-,42-/m0/s1
  • Key:PVVHQWISMVJHFK-NIFJBHDKSA-N

Merotocin (INN; developmental code FE-202767; also known as carba-1-(4-FBzlGly7)dOT) is a peptidic agonist of the oxytocin receptor that was derived from oxytocin.[3][4][5] It is under development by Ferring Pharmaceuticals for the treatment of preterm mothers with lactation failure requiring lactation support, and is in phase II clinical trials for this indication.[5] Merotocin is potent (EC50 < 0.1 nM) and highly selective (>1000-fold over the related vasopressin receptors). Its elimination half-life is approximately 30 minutes via intranasal administration.[2]

See also

[edit]

References

[edit]
  1. ↑ "Ferring pharmaceuticals". AdisInsight. 27 January 2023. Retrieved 21 July 2026.
  2. 1 2 Bagger Y, Holmqvist C, Jonker DM, Klein BM, Urban LE (November 2025). "First-in-Human Study of Merotocin, a Short-Acting Peptidic Oxytocin Receptor Agonist for Lactation Support". Clin Pharmacol Drug Dev. 14 (11): 879–888. doi:10.1002/cpdd.1581. PMC 12583980. PMID 40781993.
  3. ↑ Manning M, Misicka A, Olma A, Bankowski K, Stoev S, Chini B, Durroux T, Mouillac B, Corbani M, Guillon G (2012). "Oxytocin and vasopressin agonists and antagonists as research tools and potential therapeutics". Journal of Neuroendocrinology. 24 (4): 609–28. doi:10.1111/j.1365-2826.2012.02303.x. PMC 3490377. PMID 22375852.
  4. ↑ Yang Y, Li H, Ward R, Gao L, Wei JF, Xu TR (2014). "Novel oxytocin receptor agonists and antagonists: a patent review (2002 - 2013)". Expert Opinion on Therapeutic Patents. 24 (1): 29–46. doi:10.1517/13543776.2014.845168. PMID 24094047. S2CID 10584554.
  5. 1 2 Wiśniewski K, Alagarsamy S, Galyean R, Tariga H, Thompson D, Ly B, Wiśniewska H, Qi S, Croston G, Laporte R, Rivière PJ, Schteingart CD (2014). "New, potent, and selective peptidic oxytocin receptor agonists". J. Med. Chem. 57 (12): 5306–17. doi:10.1021/jm500365s. PMID 24874785.
[edit]


Retrieved from "https://en.wikipedia.org/w/index.php?title=Merotocin&oldid=1365338154"